Discover the research Description BPC-157 (Body Protection Compound-157) in nasal spray format provides intranasal delivery of this synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein
Direct contact between the peptide and esophageal tissue during swallowing provides local exposure in addition to systemic effects achieved after absorption
PubMed Sikiric, P., Seiwerth, S., Brcic, L., Sever, M., Klicek, R., Radic, B., Drmic, D., Ilic, S., & Kolenc, D
Clinical trials have shown that individuals taking Semaglutide may achieve an average weight loss of approximately 5-10% of their initial body weight over several months
Supplies Needed Plan based on an 816 week combined protocol with the schedules above